Posted on June 28th, 2010
Vitamin D Exposure in Childhood Linked to Age at Onset of MS
Levels of childhood sun exposure and the presence or absence of cod liver oil supplements predict age at onset of multiple sclerosis (MS), a new study suggests.
“There’s been demonstrated to be a north–south gradient in multiple sclerosis incidence, and migrating later on in life, even after a diagnosis of MS, from a colder to a warmer climate… read more »
Categories: MS Tags: multiple sclerosis, sun exposure, vitamin D supplements
Posted on June 28th, 2010
During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.
Dr. Howard Petty explains mechanism behind remission read more »
Categories: MS, Remission Tags: American Journal of Immunology, immune status, pre-eclampsia, pregnancy, Remission
Posted on June 13th, 2010
“Those who will develop MS will show a different blood signature from those who will not,” Prof. Anat Achiron, director of the Multiple Sclerosis Center at Sheba Medical Center.
Multiple sclerosis (MS) has devastated the lives of two million people around the world. MS attack read more »
Categories: Other Diagnostic Tools Tags: autoimmune disease, biomarkers in blood, blood tests, Copaxone, diagnosis, MRI, MS, multiple sclerosis, Research, Symptoms
Posted on May 05th, 2010
Scientists at the University of Pittsburgh School of Medicine went on a molecular fishing trip, and netted a catch of new mediators in our bodies that explain how omega-3 acids reduce inflammation, and also hint at novel treatments read more »
Categories: Main Page, Other Studies, Research Tags: disease treatments, Omega-3, Omega-3 Fatty Acid
Posted on April 23rd, 2010
Over the last few months, the world of multiple sclerosis has been in chaos over the intense debate of how a completely new concept, that of chronic cerebrospinal venous insufficiency (CCSVI), is part of the MS disease process. Furthermore, the debate has also included heated discussions of whether or not treatment of the CCSVI condition should be part of multiple sclerosis treatment in th read more »
Categories: chronic cerebrospinal venous insufficiency (CCSVI), Tags: autoimmune disease, CCSVI, Cerebrospinal Venous Insufficiency, clinically isolated syndrome, MS patients, neurodegeneration, neurologist, neurology, pharmaceutical, ultrasound, Zamboni
Posted on April 23rd, 2010
BARCELONA, Spain –
April 21, 2010 –
Long-term pharmacological treatment of severe overactive bladder (OAB) and detrusor overactivity with botulinum-A toxin (BoNT-A) injections is efficient and safe, according to a study presented here at the 25th Annual European Association of Urology (EAU) Congress.
Daniel Max Schmid, MD, Department of Urology, University Hospital Zurich, Zurich, Switzerland, reported the results of an 8-year follow-up on April
Categories: Bladder & Bowel Dysfunction, MS Symptoms Tags: bladder, bladder function, Botulinum, efficacy, overactive bladder, patients, urine, urology
Posted on April 18th, 2010
Explain to interested patients that fatigue is often a complaint with multiple sclerosis.
Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
TORONTO, CANADA –
Multiple sclerosis patients treated with glatiramer acetate (Copaxone) reported a trend to lessening of the fatigue caused by the disease, researchers
Categories: Depression, MS Tags: Copaxone, Expanded Disability Status Scal, Glatiramer acetate, Modified Fatigue Impact Scale, MS, multiple sclerosis
Posted on April 15th, 2010
A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.
The drug, called dalfampridine, is the first therapy for multiple sclerosis that can be taken orally. It is also the first FDA-approved therapy to treat impaired walking, a debilitating symptom of the disease limiting patients’
Categories: MS, Research Tags: MS, multiple sclerosis, progression, relapses, relapsin remitting multiple sclerosis
Posted on February 28th, 2010
the 15-year clinical study with Copaxone(R) (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis . . .
80 percent of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of patients have not transitioned to secondary progressive MS read more »
Categories: Copaxone, MS, Research, Therapies Tags: Copaxone, Depression, MS, multiple sclerosis, relapsin remitting multiple sclerosis, therapy, treatment
Posted on November 29th, 2009
The following questions ask for your views about the impact of MS on your day-to-day life during the past two weeks read more »
Categories: MS Tags: difficulty doing things, limitations in activities, MS Impact Scale, physically demanding tasks, tremor
